Poor
Needs Revision
Patient Risk:
Moderate
Summary
Most claims provided are general statements not supported or contradicted by the supplied Stromectol prescribing information excerpts. Several safety/medication-use framing claims are absent from label, limiting on-label alignment.
Category Scores
Accurate Statements
Stromectol is a brand name for ivermectin.
Supported by provided label excerpts showing the product name STROMECTOL with active ingredient ivermectin.
Unsupported Statements
Counterfeit or improperly dispensed ivermectin is a real risk.
No statement in the provided label excerpts addresses counterfeit or improper dispensing risks.
Ivermectin is not a one-size-fits-all purchase.
The provided label excerpts do not contain this concept or any label language about purchasing/choosing ivermectin formulations or products.
The safety and dosing of ivermectin depend on what it is for (for example, certain parasitic infections versus off-label uses).
The label excerpts support different labeled indications with different labeled dosing for strongyloidiasis vs onchocerciasis, but do not support claims about off-label uses or broad statements about safety/dosing depending on off-label use.
Whether a prescription is usually required depends on the indication and the country.
The provided label excerpts do not discuss prescription requirements, regulation, or country-specific dispensing rules.
Contradictions
Important Omissions
No on-label safety warnings/precautions were cited for risks that appear in the provided label excerpts (e.g., neurotoxicity, Loa loa encephalopathy risk in certain exposed patients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported general claims may mislead about risk context (counterfeit/improper dispensing; off-label framing; prescription requirement framing). However, no direct dosing or contraindication errors were made in the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts and include off-label/purchasing/regulatory assertions not addressed in the label.
Suggested Improvement
Limit statements to what the label excerpts explicitly support (e.g., labeled indications and labeled dosing differences for strongyloidiasis vs onchocerciasis; contraindication for hypersensitivity). Remove or rephrase unsupported claims about counterfeit risk, 'one-size-fits-all purchase,' off-label use, and country-specific prescription requirements.